Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHL
MCID: LYM133
MIFTS: 69

Lymphoma, Hodgkin, Classic (CHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Hodgkin, Classic

About this section

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 57 72 37 39
Hodgkin Lymphoma 57 12 73 20 58 36 13 15 32
Hodgkin Disease 57 12 20 72 54 42 70
Classic Hodgkin Lymphoma 58 29 6
Hodgkin's Lymphoma 12 20 15
Hodgkins Lymphoma 12 29 17
Chl 57 72
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 70
Hodgkin's Disease of Intrapelvic Lymph Nodes 70
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Susceptibility to 39
Hodgkin Lymphoma, Susceptibility to 57
Classic Hodgkin Disease 58
Lymphoma, Hodgkin's 20
Hodgkin's Sarcoma 12
Hodgkin's Disease 73
Hl 12

Characteristics:

Orphanet epidemiological data:

58
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;
hodgkin lymphoma
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: Adult;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive


HPO:

31
lymphoma, hodgkin, classic:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


Sources

Summaries for Lymphoma, Hodgkin, Classic

About this section
GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 98293 Definition Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B- cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. Epidemiology HL is an uncommon cancer with an incidence of about 1/40,000 in North America and Europe. There are about 8500 new cases reported in the U.S. each year. Clinical description HL is comprised of 2 major forms: classical Hodgkin lymphoma (CHL; see this term), seen in 95% of all HL cases, and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL; see this term), seen in only 5% of all HL cases. Disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. Disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients. Etiology The exact cause is unknown but immunological, genetic and environmental factors are thought to be involved. Management and treatment Treatment with radiotherapy and systemic chemotherapy leads to a very good prognosis. Follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. Possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke. Prognosis The international prognostic score (IPS) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin <4g/dl, hemoglobin <10.5 g/l, lymphocytopenia and WBC count >15,000/mm3) at the time of diagnosis. The more factors present, the less favorable the prognosis. The cure rates are 90% for early-stage HL and 70% for advance stage HL.

MalaCards based summary : Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to hodgkin's lymphoma, lymphocytic-histiocytic predominance and hodgkin's lymphoma, lymphocytic depletion. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Viral carcinogenesis. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are fatigue and immunodeficiency

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

OMIM® : 57 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000) (Updated 20-May-2021)

MedlinePlus : 42 Hodgkin disease is a type of lymphoma. Lymphoma is a cancer of a part of the immune system called the lymph system. The first sign of Hodgkin disease is often an enlarged lymph node. The disease can spread to nearby lymph nodes. Later it may spread to the lungs, liver, or bone marrow. The exact cause is unknown. Hodgkin disease is rare. Symptoms include Painless swelling of the lymph nodes in the neck, armpits, or groin Fever and chills Night sweats Weight loss Loss of appetite Itchy skin To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. Treatment depends on how far the disease has spread. It often includes radiation therapy or chemotherapy. The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. NIH: National Cancer Institute

KEGG : 36 Hodgkin's lymphoma (HL) is one of the most frequent lymphomas in the Western world and often affects young adults. HL is subdivided into classical and nodular lymphocyte-predominant forms. About 95% of cases are classical HL, and 5% are nodular lymphocyte-predominant HL (NLPHL). A characteristic feature of HL is the rareness of the tumor cells, which are called Hodgkin's and Reed/Sternberg (HRS) cells in classical HL and lymphocytic and histiocytic (L&H) cells in NLPHL. These cells represent only about 1% of the cellular infiltrate, while the vast majority of infiltrating cells are T lymphocytes, histiocytes, eosinophilic granulocytes and plasma cells. HRS cells show constitutive activity of both the classical and alternative NF-{kappa}B signalling pathways, which is probably a major pathogenetic mechanism in Hodgkin's lymphoma. The NF-{kappa}B activity in HRS cells is probably mediated by diverse mechanisms: receptor signalling through CD40, RANK, BCMA, and TACI, genomic REL amplification, destructive mutations in IKBA and IKBE. In HL pathogenesis associated with Epstein-Barr virus infection, the activation of NF-{kappa}B is induced by viral latent membrane protein 1 (LMP1).

UniProtKB/Swiss-Prot : 72 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Wikipedia : 73 Hodgkin lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white... more...

Sources

Related Diseases for Lymphoma, Hodgkin, Classic

About this section

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1893)
# Related Disease Score Top Affiliating Genes
1 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.9 TNFRSF8 BCL6
2 hodgkin's lymphoma, lymphocytic depletion 32.9 TNFRSF8 PAX5
3 hodgkin's lymphoma, nodular sclerosis 32.8 TNFRSF8 PAX5 KLHDC8B BCL6
4 t-cell/histiocyte rich large b cell lymphoma 32.6 TNFRSF8 BCL6
5 lymphoma, mucosa-associated lymphoid type 32.5 TNFRSF8 PAX5 IRF4 BCL6
6 mantle cell lymphoma 32.5 PAX5 MIR155 CSF3 BCL6
7 primary central nervous system lymphoma 32.5 PAX5 BCL6
8 t-cell lymphoma, subcutaneous panniculitis-like 32.5 TNFRSF8 ALK
9 mediastinal gray zone lymphoma 32.4 TNFRSF8 PAX5
10 mature t-cell and nk-cell lymphoma 32.4 TNFRSF8 BCL6 ALK
11 reticulosarcoma 32.3 TNFRSF8 PAX5 BCL6 ALK
12 intraocular lymphoma 32.2 PAX5 BCL6
13 gray zone lymphoma 32.2 TNFRSF8 PAX5 BCL6
14 marginal zone b-cell lymphoma 31.8 TNFRSF8 PAX5 IRF4 BCL6
15 lymphoblastic lymphoma 31.7 TNFRSF8 PAX5 BCL6
16 primary mediastinal large b-cell lymphoma 31.7 IRF4 BCL6
17 peripheral t-cell lymphoma 31.6 TNFRSF8 PAX5 BCL6 ALK
18 myeloma, multiple 31.4 PVT1 MIR30A MIR21 MIR186 MIR140 IRF4
19 bone lymphoma 31.2 TNFRSF8 IRF4 BCL6 ALK
20 dermatomyositis 31.1 MIR30A MIR21 MIR155
21 testicular lymphoma 31.1 TNFRSF8 IRF4 BCL6
22 breast lymphoma 31.1 TNFRSF8 IRF4 BCL6 ALK
23 mediastinal malignant lymphoma 31.1 TNFRSF8 PAX5
24 renal cell carcinoma, nonpapillary 31.0 PVT1 MIR30B MIR30A MIR21 MIR200A MIR18A
25 pediatric lymphoma 31.0 TNFRSF8 IRF4 BCL6 ALK
26 skin carcinoma 31.0 MIR30A MIR21 MIR140 CSF3 ALK
27 polymyositis 30.9 MIR30A MIR21 MIR155
28 multicentric castleman disease 30.9 TNFRSF8 PAX5 IRF4
29 adult lymphoma 30.9 TNFRSF8 IRF4 CSF3 BCL6 ALK
30 plasmacytoma 30.8 PVT1 PAX5 IRF4
31 waldenstroem's macroglobulinemia 30.8 PAX5 MIR155 IRF4
32 pleural empyema 30.8 TNFRSF8 PAX5 BCL6
33 arteries, anomalies of 30.8 MIR520A MIR30B MIR30A MIR21 MIR155 MIR140
34 lung lymphoma 30.7 TNFRSF8 PAX5 BCL6
35 central nervous system disease 30.7 MIR30B MIR30A MIR21 MIR18A MIR155 MIR140
36 heart lymphoma 30.6 BCL6 ALK
37 connective tissue disease 30.6 MIR30B MIR30A MIR21 MIR200A MIR18A MIR155
38 nervous system disease 30.5 MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
39 primary cutaneous anaplastic large cell lymphoma 30.5 IRF4 ALK
40 lymphosarcoma 30.4 TNFRSF8 BCL6
41 mature b-cell neoplasm 30.4 TNFRSF8 PVT1 PAX5 MIR155 IRF4 BCL6
42 follicular lymphoma 30.4 MIR155 IRF4 BCL6
43 bone inflammation disease 30.4 MIR30B MIR30A MIR21 MIR155 MIR140
44 paranasal sinus lymphoma 30.4 TNFRSF8 PAX5 BCL6
45 lymphomatoid papulosis 30.4 TNFRSF8 ALK
46 tracheal lymphoma 30.4 TNFRSF8 PAX5 BCL6
47 thyroid gland anaplastic carcinoma 30.4 MIR30A MIR18A ALK
48 anaplastic large cell lymphoma 30.4 TNFRSF8 PAX5 ALK
49 adult acute lymphocytic leukemia 30.4 TNFRSF8 PAX5 CSF3
50 retinal vascular disease 30.4 MIR30A MIR21 MIR20A

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic
Sources

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

About this section

Human phenotypes related to Lymphoma, Hodgkin, Classic:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012378
2 immunodeficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0002721
3 cellular immunodeficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0005374
4 lymphoma 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002665
5 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002716
6 hyperhidrosis 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000975
7 fever 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001945
8 anorexia 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0002039
9 cough 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0012735
10 chest pain 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0100749
11 weight loss 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001824
12 pruritus 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000989
13 poor appetite 58 31 frequent (33%) Frequent (79-30%) HP:0004396
14 ataxia 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001251
15 respiratory insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002093
16 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001744
17 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002240
18 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
19 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002105
20 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0009830
21 migraine 58 31 occasional (7.5%) Occasional (29-5%) HP:0002076
22 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
23 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
24 bone pain 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002653
25 osteolysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002797
26 bone marrow hypocellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0005528
27 neoplasm 58 Occasional (29-5%),Occasional (29-5%)
28 abnormality of blood and blood-forming tissues 58 Occasional (29-5%)
29 hodgkin lymphoma 31 HP:0012189
30 polyclonal elevation of igm 31 HP:0003459
31 impaired lymphocyte transformation with phytohemagglutinin 31 HP:0003347

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease

Clinical features from OMIM®:

236000 (Updated 20-May-2021)

Sources

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

About this section

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Pirarubicin Investigational Phase 4 72496-41-4
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Methylprednisolone Acetate Phase 4
12 Epoetin alfa Phase 4 113427-24-0
13 Hematinics Phase 4
14
Metronidazole Approved Phase 3 443-48-1 4173
15
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
16
Clarithromycin Approved Phase 3 81103-11-9 84029
17
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
20
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Chlorambucil Approved Phase 3 305-03-3 2708
24
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
25
Calcium carbonate Approved, Investigational Phase 3 471-34-1
26
Zoledronic Acid Approved Phase 3 118072-93-8 68740
27
Allopurinol Approved Phase 3 315-30-0 2094
28
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
29
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
30
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
31
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
32
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
33
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
34
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
35
Famotidine Approved Phase 3 76824-35-6 3325
36
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
37
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
38
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
39
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
40
Mycophenolic acid Approved Phase 3 24280-93-1 446541
41
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
42
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
43
Epirubicin Approved Phase 3 56420-45-2 41867
44
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
45
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
46
tannic acid Approved Phase 3 1401-55-4
47
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
48
Idarubicin Approved Phase 3 58957-92-9 42890
49
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
50
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348

Interventional clinical trials:

(show top 50) (show all 1941)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
3 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
5 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
6 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
8 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
9 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
10 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
11 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
12 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
13 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
15 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
16 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
17 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
18 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
19 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
20 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
21 A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy Recruiting NCT04726501 Phase 4
22 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
23 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
24 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
25 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
26 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
27 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
28 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
29 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
30 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
31 Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies Unknown status NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase
32 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
33 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
34 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
35 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
36 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
37 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
39 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
40 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
41 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
42 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
43 Non-Hodgkin's Lymphoma T Cell Protocol Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
44 Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
45 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
47 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
48 A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
49 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
50 Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Hodgkin, Classic:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Peripheral blood stem cells for treatment of hematologic malignancies
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Embryonic/Adult Cultured Cells Related to Lymphoma, Hodgkin, Classic:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Sources

Genetic Tests for Lymphoma, Hodgkin, Classic

About this section

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Classic Hodgkin Lymphoma 29 KLHDC8B
2 Hodgkins Lymphoma 29
Sources

Anatomical Context for Lymphoma, Hodgkin, Classic

About this section

MalaCards organs/tissues related to Lymphoma, Hodgkin, Classic:

40
T Cells, Bone Marrow, Bone, Breast, Lymph Node, Liver, Thyroid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Lymphoma, Hodgkin, Classic

About this section

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 17932)
# Title Authors PMID Year
1
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. 61 6 57
19706467 2009
2
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. 61 57 54
17539776 2007
3
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. 61 57 54
11830502 2002
4
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. 61 57
21368758 2011
5
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. 57 54
20436485 2010
6
A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. 57 61
15994882 2005
7
Localization of predisposition to Hodgkin disease in the HLA class II region. 57 61
8116619 1994
8
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. 42 61
33641019 2021
9
Melittin Increases Cisplatin Sensitivity and Kills KM-H2 and L-428 Hodgkin Lymphoma Cells. 61 42
33396195 2020
10
Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma. 61 42
33370316 2020
11
Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. 47 61
19775296 2009
12
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. 57
14523140 2003
13
Infection and lymphoma. 57
14523136 2003
14
Combined segregation and linkage analysis of 59 Hodgkin's disease families indicates the role of HLA determinants. 57
10878668 2000
15
A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. 57
10914686 2000
16
Familial Hodgkin's disease: a disease of young adulthood? 57
9111426 1997
17
Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. 57
7824015 1995
18
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. 57
8381153 1993
19
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. 57
1671232 1991
20
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. 57
2172169 1990
21
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. 57
2537928 1989
22
Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. 57
2536894 1989
23
Epstein-Barr viral DNA in tissues of Hodgkin's disease. 57
2821817 1987
24
HLA in familial Hodgkin's disease. 57
6875280 1983
25
Simultaneous Hodgkin's disease in three siblings with identical HLA-genotype. 57
7397649 1980
26
Infectious mononucleosis and Hodgkin's disease. 57
681023 1978
27
Serum genetic markers in a Newfoundland isolate with a familial aggregate of Hodgkin's disease. 57
680699 1978
28
HLA in familial Hodgkin's disease. Results and a new hypothesis;. 57
844915 1977
29
Hodgkin's disease in siblings. 57
831107 1977
30
Familial Hodgkin's disease and the major histocompatibility complex. 57
144365 1977
31
Familial Hodgkin's disease and associated cancer. A clinical-pathologic study. 57
991117 1976
32
Varied manifestations of a familial lymphoproliferative disorder. 57
806230 1975
33
Familial Hodgkin's disease: an environmental and genetic disorder. 57
4137662 1974
34
Family studies in Hodgkin's disease. 57
4842358 1974
35
Familial Hodgkin's disease. 57
4115609 1972
36
Mortality from Hodgkin's disease in the United States. Evidence for the multiple-aetiology hypothesis. 57
4177934 1968
37
Epidemiology of Hodgkin's disease. 57
5329907 1966
38
[FAMILIAL HODGKIN'S DISEASE]. 57
14154061 1964
39
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. 54 61
20065852 2010
40
B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. 61 54
20398809 2010
41
IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. 61 54
19804451 2010
42
Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. 54 61
20093237 2010
43
Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. 54 61
19931589 2010
44
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. 61 54
20093413 2010
45
IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. 61 54
19821826 2010
46
Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. 54 61
19550297 2010
47
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. 54 61
19734449 2009
48
Low apoptotic index & bak expression in EBV-associated childhood classical Hodgkin lymphoma. 54 61
20090100 2009
49
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. 54 61
19666866 2009
50
STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. 61 54
19440213 2009
Sources

Variations for Lymphoma, Hodgkin, Classic

About this section

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KLHDC8B NM_173546.3(KLHDC8B):c.-158C>T SNV Pathogenic 273 rs387906223 GRCh37: 3:49209095-49209095
GRCh38: 3:49171662-49171662

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

7 (show top 50) (show all 204)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma
Sources

Expression for Lymphoma, Hodgkin, Classic

About this section
Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.
Sources

Pathways for Lymphoma, Hodgkin, Classic

About this section

Pathways related to Lymphoma, Hodgkin, Classic according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 Viral carcinogenesis hsa05203
3 Epstein-Barr virus infection hsa05169

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.97 TNFRSF8 PAX5 IRF4 BCL6
2
MicroRNAs in cancer 36
11.72 MIR520A MIR30B MIR30A MIR21 MIR20A MIR200A
3
Parkinsons Disease Pathway 1
11.06 MIR30A MIR20A MIR18A
Sources

GO Terms for Lymphoma, Hodgkin, Classic

About this section

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR374A MIR30B MIR30A MIR21 MIR20A MIR18A
2 extracellular vesicle GO:1903561 9.26 MIR30B MIR30A MIR21 MIR20A

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.78 MIR21 MIR20A MIR155 MIR140
2 cellular response to lipopolysaccharide GO:0071222 9.67 MIR21 MIR20A MIR140 CSF3
3 miRNA mediated inhibition of translation GO:0035278 9.63 MIR21 MIR20A MIR155
4 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.61 MIR21 MIR155 MIR140
5 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.51 MIR21 MIR140
6 negative regulation of innate immune response GO:0045824 9.49 MIR21 MIR155
7 positive regulation of activated T cell proliferation GO:0042104 9.43 MIR30B MIR21 MIR155
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR20A MIR155
9 gene silencing by miRNA GO:0035195 9.36 MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A
10 negative regulation of cell adhesion molecule production GO:0060354 9.33 MIR374A MIR20A MIR155
11 positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching GO:1905932 9.32 MIR18A MIR140
12 negative regulation of regulatory T cell differentiation GO:0045590 9.13 MIR30B MIR21 MIR155

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR374A MIR30A MIR21 MIR20A MIR186 MIR140
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A
Sources

Sources for Lymphoma, Hodgkin, Classic

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....